Mostrando 2 resultados de: 2
A Phase III Clinical Trial of the Epidermal Growth Factor Vaccine CIMAvax-EGF as Switch Maintenance Therapy in Advanced Non-Small Cell Lung Cancer Patients
ArticleAbstract: Purpose: EGFR is a well-validated target for patients with non-small cell lung cancer (NSCLC). CIMAvPalabras claves:Autores:Acosta S.C., Aguilera N., Alonso L., Amador R.M., Arzuaga L., Cala M., Carmen Elena Viada, Catala M., Crespo T., De La Torre A.V., Fleytas R., Flores Y.I., Futiel N., García Verdecia B., Lage Davila A., Luaces P.L.o., Marrero Miragaya M.A., Martínez O., Mazorra Z., Mendoza S., Neninger Vinageras E., Otero Y., Parra J., Pomares Y., Popa X., Reyes D., Rodríguez G., Rodríguez P.C., Romero G.N., Sabates T., Santiesteban E.R., Sierra P., Tania Crombet, Vello L.Fuentes:scopusEvaluation of quality of life in patients with non-small cell lung cancer treated with CIMAvaxEGF® vaccine
ArticleAbstract: This report corresponds to quality of life analysis of patient with non-small cell lung cancer incluPalabras claves:Cancer Vaccines, clinical trials, Non-small cell lung cancer, quality of life, surveys and questionnairesAutores:Álvarez-Cardona M., Carmen Elena Viada, Crombet-Ramos T., Frías-Blanco A., Lorenzo-Monteagudo G., Neninger-Vinagera E., Ramos-Suzarte M., Rodríguez P.C.Fuentes:scopus